May 19, 2020

[INFOGRAPHIC] How each state stacks up in CommSec's quarterly report

Commonwealth Bank of Australia
2 min
[INFOGRAPHIC] How each state stacks up in CommSec's quarterly report

According to the latest quarterly State of the States report by Commonwealth Bank of Australia’s Commonwealth Securities (CommSec), New South Wales is Australia’s most thriving economy for the fifth-straight quarter.

NSW holds the top spot just ahead of Victoria based on strong population growth, retail trade, dwelling starts and housing finance. Other factors in the rankings include unemployment, equipment investment, construction growth and overall economic growth.

RELATED TOPIC: Asia Pacific holds spot as top wealth market in the world

While it struggled with economic growth, Victoria’s strength in housing finance helped propel it into second place. Meanwhile, NSW ranked second in both unemployment and equipment investment, while it finished fourth in construction growth and fifth in economic growth.

Third-ranked Northern Territory excelled in equipment spending, but had weak population growth. Western Australia excelled in economic growth, however struggled with unemployment to land in fourth.

Queensland ranked fifth behind a low unemployment rate, while the Australian Capital Territory has seen strength in housing finance to land sixth.

RELATED TOPIC: Australia places 10th globally in higher education ranking

As the disparity between NSW and the rest continues to increase, South Australia is in danger of falling behind Tasmania, which is showing signs of momentum despite being ranked eighth.

While SA is third overall in both equipment investment and population growth, Tasmania now has the lowest unemployment rate and is third in housing finance.

With a downturn in manufacturing along with the upcoming closure of the state’s auto industry and a weaker Aussie dollar, business has been increasingly tough for exporters. Because of this, SA’s eight per cent unemployment rate is the highest it has been in 15 years, while Tasmania’s 6.2 per cent rate is nearly a four-year low.

RELATED TOPIC: Australia suffers slight drop in Global Competitiveness Ranking

Similarly to how Tasmania’s economy was previously sparked by assistance from the state and federal government, South Australia may soon require similar support.

Below is a graphic of the most recent rankings:


Let's connect!  

Check out the latest edition of Business Review Australia!

Share article

Jun 13, 2021

Seo JungJin: Who is EY’s World Entrepreneur of 2021?

Kate Birch
3 min
From just US$45,000 capital in 2003 to a world-leading biopharma giant with revenues of US$1.69bn today, Seo JungJin is crowned EY World Entrepreneur 2021

Seo JungJin, founder of biopharma firm Celltrion, which most recently developed an antibody treatment for COVID-19, has been named the EY World Entrepreneur of the Year 2021, becoming the first South Korean in the award’s 21-year history.

Regarded as one of the world’s most prestigious business awards program for entrepreneurs, the EY Entrepreneur of the Year celebrates visionary and innovative leaders from across 60 countries who are transforming the world and fostering growth.

JungJin, who is now honoroary chairman of Celltrion Group, was up against a worthy cast of entrepreneurial competitors, taking the crown from among 45 award winners across 38 countries and territories.

Speaking during the virtual event, JungJin described his own interpretation of entrepreneurship as something that brings together “a group of people toward a common vision, embracing challenges as opportunities and committing oneself to contribute to the greater good”.

Why was JungJin crowned King Entrepreneur?

A South Korean native and now 63 years of age, JungJin founded biopharmaceutical firm Celltrion in 2003. In the nearly two decades since its founding, Celltrion has lived up to its goal of advancing health and welfare for all by developing ground-breaking drugs to treat autoimmune disease, various forms of cancer and, most recently, COVID-19.

The company, which JungJin started with just US$45,000 and five of his colleagues, has since growth to more than 2,1000 employees with sales permits in more than 90 countries and revenues exceeding US$1.69bn.

According to the panel, JungJin’s story is a shining example of the power of an unstoppable entrepreneur to change the world with the pandel moved by both his incredible story and his purpose-driven leadership, innovative mindset and entrepreneurial spirit.

Described by the chair of the EY judging panel Rosaleen Blair as “representing everything an unstoppable should be” from taking on the world’s biggest health care challenges to consistently creating long-term value for his company, JungJin’s story is one of incredible tenacity and perseverance that the judging panel felt most represented the entrepreneurial spirit.

“He’s taken breathtaking risks, both personal and professional, to found Celltrion and grow it into one of the world’s leading biopharmaceutical companies,” says Stasia Mitchell, EY Global Entrepreneurship Leader. “His passion for creating affordable, life-saving health care and flair for tackling global problems has led to many treatments that have helped millions of people worldwide and was especially evident this past year through the creation of a COVID-19 antibody treatment.”

How did JungJin get there?

JungJin's entrepreneurial journey started at an early age when he worked as a taxi driver to get himself through Konkuk University in Seoul, South Korea. After studying industrial engineering, he rose through the ranks of Daewoo Motor Co. before losing his job amid the carmaker’s financial troubles following the 1997 Asian economic crisis.

Following this, JungJin started collaborating with colleagues to explore business opportunities in different industries, though none delivered lasting success. The turning point came after he attended a talk hosted by renowned scholars, which inspired him to focus on the biopharmaceutical sector.

And so he founded Celltrion with just US$45,000 of his savings. The launch of Remsima, credited with being the world's first antibody biosimilar, quickly moved Celltrion up the ranks of the country's fairly underdeveloped pharmaceutical sector. Celltrion followed this success with the launch of drugs for breast cancer and lymphoma that today are being used worldwide.

With ambitions to be the world’s first in different areas, Celltrion has pioneered numerous uncharted areas to great success over the past two decades, most recently responding to the global pandemic by successfully developing an antibody treatment for COVID-19 and working to ensure a timely supply of the safe and effective treatment.

“When I first started, my vision was to help patients gain access to safe, effective and affordable medicines and thereby enhance the quality of people’s lives,” explains JungJin. “The success of Celltrion has enabled me to expand on this while finding new ways to fuel my entrepreneurial drive.”


Share article